Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Neoplasms × trifluridine tipiracil drug combination × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 62 Colonic Neoplasms 13 Rectal Neoplasms 12 Neoplasm Metastasis 10 Stomach Neoplasms 7 Pancreatic Neoplasms 5 Advanced Solid Tumors 5 Gallbladder Neoplasms 3 Colorectal Cancer Metastatic 3 Cholangiocarcinoma 3 Carcinoma 3 Adenocarcinoma 3 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Carcinoma, Non-Small-Cell Lung 2 Biliary Tract Neoplasms 2 Bile Duct Neoplasms 2 Advanced Solid Tumors (Excluding Breast Cancer) 2 Advanced Colorectal Cancer 2 Adenocarcinoma Of Esophagus 2 mCRC 1 Urologic Diseases 1 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Spinocerebellar Degenerations 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 Sarcoma, Alveolar Soft Part 1 Renal Insufficiency 1 Refractory Solid Tumors 1 Recurrence 1

Interventions

Trastuzumab 556 Paclitaxel 513 Cyclophosphamide 491 Docetaxel 431 Capecitabine 372 Letrozole 336 Fulvestrant 292 Doxorubicin 262 Tamoxifen 245 Carboplatin 243 Anastrozole 211 Radiotherapy 201 exemestane 199 Epirubicin 180 Bevacizumab 178 palbociclib 170 Lapatinib 156 Vinorelbine 155 pertuzumab 152 Gemcitabine 151 pembrolizumab 146 Surveys and Questionnaires 124 Exercise 119 Magnetic Resonance Spectroscopy 117 eribulin 108 Albumin-Bound Paclitaxel 108 Fluorouracil 105 Blood Specimen Collection 103 130-nm albumin-bound paclitaxel 99 Everolimus 94

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04489173 2025-09-19

TIBET

Borstkanker Onderzoek Groep

Phase 2 Active not recruiting

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡